Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs

Guntram Schernthaner, Avraham Karasik, Agne Abraitienė, Alexander S. Ametov, Zsolt Gaàl, Janusz Gumprecht, Andrej Janež, Susanne Kaser, Katarina Lalić, Boris N. Mankovsky, Evgeny Moshkovich, Marju Past, Martin Prázný, Gabriela Radulian, Lea Smirčić Duvnjak, Ivan Tkáč, Kārlis Trušinskis

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)
3 Downloads (Pure)


EMPA-REG OUTCOME is recognised by international guidelines as a landmark study that showed a significant cardioprotective benefit with empagliflozin in patients with type 2 diabetes (T2D) and cardiovascular disease. To assess the impact of empagliflozin in routine clinical practice, the ongoing EMPRISE study is collecting real-world evidence to compare effectiveness, safety and health economic outcomes between empagliflozin and DPP-4 inhibitors. A planned interim analysis of EMPRISE was recently published, confirming a substantial reduction in hospitalisation for heart failure with empagliflozin across a diverse patient population. In this commentary article, we discuss the new data in the context of current evidence and clinical guidelines, as clinicians experienced in managing cardiovascular risk in patients with T2D. We also look forward to what future insights EMPRISE may offer, as evidence is accumulated over the next years to complement the important findings of EMPA-REG OUTCOME.

Original languageEnglish
Article number115
JournalCardiovascular Diabetology
Issue number1
Publication statusPublished - 31 Aug 2019


  • CVOTs
  • Heart failure
  • Real-world evidence
  • Type 2 diabetes

Field of Science*

  • 3.2 Clinical medicine

Publication Type*

  • 1.1. Scientific article indexed in Web of Science and/or Scopus database


Dive into the research topics of 'Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs'. Together they form a unique fingerprint.

Cite this